Abstract
No public abstract is available from the verified source records.
Fatemeh Tirgar, Mina Hosseini, Sakineh Alijanpour, Mohamad-Reza Aghanoori, Sahar Alijanpour, Hami Mahdavinataj
Abstract
Authors
Institutions
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Data from ENROLL-HD: is the prevalence of juvenile and pediatric Huntington’s disease overestimated?
10.1016/j.parkreldis.2021.05.012 · 2021
Guofang Xue, The role of neuroinflammation in neurodegenerative diseases: current understanding and future therapeutic targets
10.3389/fnagi.2024.1347987 · 2024
Mitochondria and reactive oxygen species
10.1161/hypertensionaha.109.130054 · 2009
RNAi mechanisms in Huntington’s disease therapy: siRNA versus shRNA
10.1186/s40035-017-0101-9 · 2017
Unresolved referenced work
2025
CRISPR/Cas9 Mediated Therapeutic Approach in Huntington’s Disease
10.1007/s12035-022-03150-5 · 2023
Astrocyte-neuron metabolic relationships: for better and for worse
10.1016/j.tins.2010.12.001 · 2011
A divalent siRNA chemical scaffold for potent and sustained modulation of gene expression throughout the central nervous system
10.1038/s41587-019-0205-0 · 2019
Delivery of mutant huntingtin-lowering antisense oligonucleotides to the brain by intranasally administered apolipoprotein A-I nanodisks
10.1016/j.jconrel.2023.07.027 · 2023
Provenance
crossref
Confidence 100%
ror
Confidence 99%
ror
Confidence 99%
openalex
Confidence 95%
datacite
Confidence 0%
Clinical management of neuropsychiatric symptoms of huntington disease: expert-based consensus guidelines on agitation, anxiety, apathy, psychosis and sleep disorders
10.3233/jhd-180293 · 2018
Psychotropic medication use in Huntington’s disease: a retrospective cohort study
10.1016/j.parkreldis.2022.11.004 · 2022
Rapid eye movement sleep disturbances in Huntington disease
10.1001/archneur.65.4.482 · 2008
Juvenile Parkinson’s disease and its response to L-dopa therapy
10.1007/bf02251243 · 1990
International guidelines for the treatment of Huntington’s disease
10.3389/fneur.2019.00710 · 2019
The frequency of huntington disease and huntington disease-like 2 in the South African population
10.1159/000444020 · 2016
Prevalence of juvenile-onset and pediatric Huntington’s disease and their availability and ability to participate in trials: a Dutch population and Enroll-HD observational study
10.3233/jhd-240034 · 2024
Juvenile-Onset Huntington Disease Pathophysiology and Neurodevelopment: a Review
10.1002/mds.28823 · 2022
Disassociation of histone deacetylase-3 from normal huntingtin underlies mutant huntingtin neurotoxicity
10.1523/jneurosci.5831-12.2013 · 2013
Huntingtin-Mediated Multipolar-Bipolar Transition of Newborn Cortical Neurons Is Critical for Their Postnatal Neuronal Morphology
10.1016/j.neuron.2016.11.035 · 2017
Huntingtin and the Synapse
10.3389/fncel.2021.689332 · 2021
The effects of multidisciplinary rehabilitation on neuroimaging, biological, cognitive and motor outcomes in individuals with premanifest Huntington’s disease
10.1016/j.jns.2020.117022 · 2020
Huntingtin aggregation and toxicity in Huntington’s disease
10.1016/s0140-6736(03)13304-1 · 2003
Huntington disease
10.1038/nrdp.2015.5 · 2015
Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid
10.1523/jneurosci.13-10-04181.1993 · 1993
Huntingtin modulates transcription, occupies gene promoters in vivo, and binds directly to DNA in a polyglutamine-dependent manner
10.1523/jneurosci.2126-08.2008 · 2008
D1R- and D2R-Medium-Sized Spiny Neurons Diversity: insights Into Striatal Vulnerability to Huntington’s Disease Mutation
10.3389/fncel.2021.628010 · 2021
Calcium signaling and neurodegenerative diseases
10.1016/j.molmed.2009.01.001 · 2009
A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington’s disease
10.1084/jem.20080178 · 2008
The effects of modafinil on mood and cognition in Huntington’s disease
10.1007/s00213-008-1068-0 · 2008
Pharmacologic Approaches for the Management of Apathy in Neurodegenerative Disorders
10.3389/fphar.2019.01581 · 2020
Mutant huntingtin in glial cells exacerbates neurological symptoms of huntington disease mice
10.1074/jbc.m109.083287 · 2010
Spinal subpial delivery of AAV9 enables widespread gene silencing and blocks motoneuron degeneration in ALS
10.1038/s41591-019-0674-1 · 2020
Mitochondrial Permeability Transition: a Molecular Lesion with Multiple Drug Targets
10.1016/j.tips.2018.11.004 · 2019
Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates
10.1073/pnas.92.15.7105 · 1995
Recent advances in the management of choreas
10.1177/1756285612471700 · 2013
A Systematic Review of Rehabilitation for Corticobulbar Symptoms in Adults with Huntington’s Disease
10.3233/jhd-190384 · 2020
Late-onset Huntington’s disease with 40–42 CAG expansion
10.1007/s10072-019-04177-8 · 2020
Systemic delivery of mutant huntingtin lowering antisense oligonucleotides to the brain using apolipoprotein A-I nanodisks for Huntington disease
10.1016/j.jconrel.2024.01.011 · 2024
Treating the whole body in Huntington’s disease
10.1016/s1474-4422(15)00177-5 · 2015
Huntingtin as an essential integrator of intracellular vesicular trafficking
10.1016/j.tcb.2009.01.005 · 2009
Molecular mechanisms and potential therapeutical targets in Huntington’s disease
10.1152/physrev.00041.2009 · doi-reference
Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes
10.1038/ng1219 · doi-reference
Huntingtin inhibits caspase-3 activation
10.1038/sj.emboj.7601445 · doi-reference
In vitro analysis of huntingtin-mediated transcriptional repression reveals multiple transcription factor targets
10.1016/j.cell.2005.10.030 · doi-reference
Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington’s disease gene homologue
10.1038/ng1095-155 · doi-reference
Allele-selective transcriptional repression of mutant HTT for the treatment of Huntington’s disease
10.1038/s41591-019-0478-3 · doi-reference
Genomic analysis of reactive astrogliosis
10.1523/jneurosci.6221-11.2012 · doi-reference
Treatment of Depression in Huntington’s Disease: a Systematic Review
10.1176/appi.neuropsych.20230120 · doi-reference
Disrupted GABA AR trafficking and synaptic inhibition in a mouse model of Huntington’s disease
10.1016/j.nbd.2012.02.015 · doi-reference
Advantages and differences among various animal models of Huntington’s disease
10.20517/and.2024.13 · doi-reference
A randomised feasibility study of computerised cognitive training as a therapeutic intervention for people with Huntington’s disease (CogTrainHD)
10.1186/s40814-020-00623-z · doi-reference
CRISPR/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington’s disease
10.1172/jci92087 · doi-reference
SQSTM1/p62 droplet -mediated autophagosome formation:insights into Huntington disease
10.1080/15548627.2021.1953820 · doi-reference
Reversal of neuropathology and motor dysfunction in a conditional model of Huntington’s disease
10.1016/s0092-8674(00)80623-6 · doi-reference
Vectors in CRISPR Gene Editing for Neurological Disorders: challenges and Opportunities
10.1002/adbi.202400374 · doi-reference
Transcriptional dysregulation and post-translational modifications in polyglutamine diseases: from pathogenesis to potential therapeutic strategies
10.3389/fnmol.2018.00153 · doi-reference
Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Hungtington’s disease
10.1093/hmg/10.17.1829 · doi-reference
Risk of VMAT2 inhibitors on suicidality and parkinsonism: report utilizing the United States Food and Drug Administration adverse event reporting system
10.1097/yic.0000000000000553 · doi-reference
Inactivation of the Huntington’s disease gene (Hdh) impairs anterior streak formation and early patterning of the mouse embryo
10.1186/1471-213x-5-17 · doi-reference
The contribution of glial cells to Huntington’s disease pathogenesis
10.1016/j.nbd.2020.104963 · doi-reference
Therapies targeting DNA and RNA in Huntington’s disease
10.1016/s1474-4422(17)30280-6 · doi-reference
Huntingtin differentially regulates the axonal transport of a sub-set of Rab-containing vesicles in vivo
10.1093/hmg/ddv415 · doi-reference
CAG Expansion in the Huntington Disease Gene Is Associated with a Specific and Targetable Predisposing Haplogroup
10.1016/j.ajhg.2009.02.003 · doi-reference
The pathobiology of perturbed mutant huntingtin protein–protein interactions in Huntington’s disease
10.1111/jnc.14853 · doi-reference
Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington’s disease
10.1038/nm.3514 · doi-reference
CRISPR-Based Therapeutic Genome Editing: strategies and In Vivo Delivery by AAV Vectors
10.1016/j.cell.2020.03.023 · doi-reference
Adeno-associated virus vector as a platform for gene therapy delivery
10.1038/s41573-019-0012-9 · doi-reference
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010
10.1016/s0140-6736(12)61729-2 · doi-reference
Traffic signaling: new functions of huntingtin and axonal transport in neurological disease
10.1016/j.conb.2020.04.001 · doi-reference
A clinical classification acknowledging neuropsychiatric and cognitive impairment in Huntington’s disease
10.1186/s13023-014-0114-8 · doi-reference
Wild-type and mutant huntingtins function in vesicle trafficking in the secretory and endocytic pathways
10.1006/exnr.1998.6832 · doi-reference
Acetylcholinesterase inhibitors in cognitive impairment in Huntington’s disease: a brief review
10.5498/wjp.v3.i3.62 · doi-reference
Beyond the brain: widespread pathology in Huntington’s disease
10.1016/s1474-4422(09)70178-4 · doi-reference
Lowering Mutant Huntingtin Levels and Toxicity: autophagy-Endolysosome Pathways in Huntington’s Disease
10.1016/j.jmb.2019.11.012 · doi-reference
Animal models of Huntington’s disease and their applicability to novel drug discovery and development
10.1080/17460441.2023.2201493 · doi-reference
Antipsychotic drugs in Huntington’s disease
10.1080/14737175.2016.1226134 · doi-reference
Delivery of GABAARs to Synapses Is Mediated by HAP1-KIF5 and Disrupted by Mutant Huntingtin
10.1016/j.neuron.2009.12.007 · doi-reference
Microglial activation in the pathogenesis of Huntington’s Disease
10.3389/fnagi.2017.00193 · doi-reference
Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases
10.1016/j.neuroscience.2006.10.056 · doi-reference
HTT-lowering reverses Huntington’s disease immune dysfunction caused by NFκB pathway dysregulation
10.1093/brain/awt355 · doi-reference